We can’t show the full text here under this license. Use the link below to read it at the source.
Killing cancer takes guts: lessons learned from the manipulation of gut microbiome and immunotherapy for the future of urothelial carcinoma
How Changing the Gut Microbiome May Help Immunotherapy Fight Bladder Cancer
AI simplified
Abstract
Immune checkpoint inhibitors may be influenced by specific gut microbiome compositions in patients with urothelial carcinoma.
- Certain gut microbiome compositions are associated with enhanced antitumor immunity and improved responses to immune checkpoint inhibitors.
- Early studies indicate that specific microbial groups can influence immune system functions such as T cell priming and cytokine production.
- Methods like , probiotic supplementation, and dietary changes have shown potential in modifying the gut microbiome to enhance outcomes.
- Transplanting taxa from immunotherapy responders into treatment-naive or prior nonresponders may lead to beneficial effects.
- Ongoing clinical trials are exploring the role of gut microbiome manipulation in improving immunotherapy results for urothelial carcinoma patients.
AI simplified
Key numbers
1.8×
1.8× Longer Recurrence-Free Interval
In a trial of 58 patients with superficial bladder cancer.
66.7%
66.7% 1-Year Progression-Free Survival
Preliminary results from the TACITO trial in metastatic renal cell carcinoma.
9 of 10
9 of 10 Treatment-Naive Patients Responded
In a study involving 10 patients refractory to PD-1 blockade.